Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS

Krishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency and better tolerability. Elvitegravir (EVG) i...

Full description

Bibliographic Details
Main Author:	Pandey KK
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-05-01
Series:	HIV/AIDS: Research and Palliative Care
Online Access:	http://www.dovepress.com/critical-appraisal-of-elvitegravir-in-the-treatment-of-hiv-1aids-a16863

Similar Items

Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS
by: Prinapori R, et al.
Published: (2015-08-01)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
by: Neamati Nouri, et al.
Published: (2009-04-01)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
by: Neamati Nouri, et al.
Published: (2009-03-01)

An Elvitegravir Nanoformulation Crosses the Blood–Brain Barrier and Suppresses HIV-1 Replication in Microglia
by: Yuqing Gong, et al.
Published: (2020-05-01)

Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method.
by: Narasimha M Midde, et al.
Published: (2016-01-01)

Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages
by: Yuqing Gong, et al.
Published: (2017-12-01)

Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal
by: Seddon J, et al.
Published: (2011-04-01)

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and HBV co-infection
by: Y.-S. Huang, et al.
Published: (2019-07-01)

Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells.
by: Narasimha M Midde, et al.
Published: (2017-01-01)

Inhibition of lipid synthesis by the HIV integrase strand transfer inhibitor elvitegravir in primary rat oligodendrocyte cultures
by: Hubert Monnerie, et al.
Published: (2023-12-01)

Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study
by: Javier Perez Stachowski, et al.
Published: (2022-08-01)

Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study
by: Nathalie De Castro, et al.
Published: (2023-01-01)

Curcumin enhances elvitegravir concentration and alleviates oxidative stress and inflammatory response
by: Sandip Godse, et al.
Published: (2023-11-01)

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
by: Marianne Harris, et al.
Published: (2017-11-01)

Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention
by: M. Melissa Peet, et al.
Published: (2024-03-01)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
by: Inès Devred, et al.
Published: (2023-09-01)

Iatrogenic Adrenal Insufficiency Secondary to Combination Therapy with Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Interlaminar Triamcinolone Injection in an AIDS Patient
by: Chanie Wassner PharmD, BCCCP, et al.
Published: (2017-11-01)

Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV
by: Huan Xia, et al.
Published: (2021-12-01)

Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy
by: Jen-Yu Hsu, et al.
Published: (2022-06-01)

1-CRITICAL APPRAISAL
by: Thamer A Hamdan
Published: (2008-06-01)

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
by: Maureen Oliveira, et al.
Published: (2018-08-01)

Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.
by: Mark A Winters, et al.
Published: (2012-01-01)

Fluorescent protein aided insights on plastids and their extensions: A critical appraisal.
by: Kathleen eDelfosse, et al.
Published: (2016-01-01)

Websites for critical appraisal in diagnosis and treatment
by: Aldemar Araújo Castro

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
by: Anthony M. Mills, et al.
Published: (2019-11-01)

Appraisal of oral lesions status of HIV/AIDS patients in South Western Uganda
by: Ezera Agwu, et al.
Published: (2016-01-01)

Critical Appraisal
by: Prof. Dr. S. Akhtar Hussain Bokhari
Published: (2020-01-01)

Critical Appraisal
by: manijeh eskandari, et al.
Published: (2011-10-01)

Critical appraisal of bevacizumab in the treatment of ovarian cancer
by: Yoshida H, et al.
Published: (2015-04-01)

Critical appraisal of paroxetine for the treatment of vasomotor symptoms
by: Carroll DG, et al.
Published: (2015-06-01)

Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaquesResearch in context
by: Natalia Makarova, et al.
Published: (2022-12-01)

HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases
by: S. Lena Kang-Birken PharmD, et al.
Published: (2019-01-01)

A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir
by: Andrea R. Thurman, et al.
Published: (2023-04-01)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

An Introduction to Critical Appraisal
by: Virginia Wilson
Published: (2010-03-01)

An Introduction to Critical Appraisal
by: Virginia Wilson
Published: (2016-03-01)

An Introduction to Critical Appraisal
by: Virginia Wilson
Published: (2010-03-01)

Critical appraisal of the literature
by: ÁLIDA ROSÁRIA SILVA FERREIRA, et al.
Published: (2021-05-01)

An Introduction to Critical Appraisal
by: Virginia Wilson
Published: (2016-03-01)

Management of Patients with Treatment of Pheochromocytoma: A Critical Appraisal
by: Florence Bihain, et al.
Published: (2022-08-01)